Pay in 4 interest-free payments of $28.75 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
CBB1007 was Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC50 ≥ 100 μM)
9)10/h2-12
CAS Number: 28721-07-5
Smiles: N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
Smiles: CC(=O)N(CCCCNC(=O)COC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O)C1N=C(C2=C(SC(C)=C2C)N2C1=NN=C2C)C1C=CC(Cl)=CC=1
NKP-1339 Catalog No.:M10117-2 CBB1007 was Shown to preferentiallyNKP 1339, aslo known as IT 139 and KP 1339, is a ruthenium based anticancer drug in clinical development against solid cancer with limited side effects. NKP 1339 shows promising results in solid tumors, such as non small cell lung cancer, colorectal carcinoma, and most distinctively in gastrointestinal neuroendocrine tumors. Product information CAS Number: 197723 00 5 Molecular Weight: 502. 14 Formula: C14H12Cl4N4NaRu Synonym: IT 139 KP 1339 Chemical
US$ 5497.50
US$ 5725.00
US$ 4296.00
US$ 2577.50
US$ 18.00
US$ 326504.00
US$ 6656.00
US$ 4984.88
US$ 9198.00